Compare Endeavour Silver Corp (EXK) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Summit Therapeutics Inc — how do they compare? Endeavour Silver Corp trades at $10.59 (market cap $3.14B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 3.8× Endeavour Silver Corp's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EXK | SMMT | |
|---|---|---|
Market Cap | $3.14B | $12.06B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $26.98 |
52-Week Low | $5.31 | $12.55 |
Enterprise Value | $3.14B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK trades at $10.61, up 3.61% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.50. Recent Q2 2026 earnings matched estimates at $0.15 per share, while Q1 2026 beat expectations. The company reported strong production growth and secured a $25 million credit facility in August 2026, supporting operational expansion.
Outlook is positive due to rising revenue, improved profitability projected for 2026, and favorable metal prices. Risks include high P/E ratio of 52.95, volatile earnings history, and dependence on commodity markets. Institutional sentiment is bullish with 78.57% buy ratings.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
